CVE-2015-0398 in Siebel Life Sciences
Summary
by MITRE
Unspecified vulnerability in the Siebel Life Sciences component in Oracle Siebel CRM 8.1.1 and 8.2.2 allows remote authenticated users to affect confidentiality via unknown vectors related to Clinical Trip Report.
If you want to get the best quality for vulnerability data then you always have to consider VulDB.
Analysis
by VulDB Data Team • 03/05/2022
The vulnerability identified as CVE-2015-0398 resides within the Siebel Life Sciences component of Oracle Siebel CRM version 8.1.1 and 8.2.2, representing a significant security weakness that could compromise data confidentiality. This issue specifically impacts the Clinical Trip Report functionality, which is a critical component in life sciences and pharmaceutical industries where sensitive patient data and clinical trial information are managed. The vulnerability affects authenticated remote users, meaning that an attacker who has already gained legitimate credentials can exploit this weakness to access confidential information without additional authentication requirements.
The technical nature of this vulnerability falls under the category of information disclosure, where the unspecified attack vectors related to Clinical Trip Report functionality enable unauthorized access to sensitive data. This type of vulnerability typically stems from inadequate input validation, improper access controls, or flawed data handling mechanisms within the Siebel Life Sciences component. The fact that the vectors remain unspecified suggests that the exact technical implementation flaw has not been fully documented in public sources, but the impact on confidentiality is clearly established. Such vulnerabilities often manifest through improper authorization checks, where authenticated users can access data beyond their intended permissions or through manipulation of data flow within the clinical reporting system.
The operational impact of this vulnerability extends beyond simple data exposure, particularly in regulated environments where compliance with healthcare data protection standards is mandatory. Organizations utilizing Oracle Siebel CRM for life sciences applications face potential regulatory violations and legal consequences if patient data or proprietary clinical information is compromised through this vulnerability. The remote nature of the attack means that threat actors can exploit this weakness from external networks, increasing the attack surface and reducing the effectiveness of traditional network-based security controls. This vulnerability could lead to unauthorized access to clinical trial data, patient records, or proprietary research information that could be monetized or used for competitive advantage.
Organizations should implement immediate mitigations including applying the relevant Oracle security patches and updates to address the vulnerability in Siebel CRM 8.1.1 and 8.2.2 versions. Network segmentation and enhanced monitoring of Clinical Trip Report functionality should be implemented to detect anomalous access patterns. Access controls should be reviewed and strengthened to ensure proper authorization checks are enforced. This vulnerability aligns with CWE-284, which addresses improper access control, and may map to ATT&CK techniques involving privilege escalation or credential access. Regular security assessments of Siebel CRM components, particularly those handling sensitive clinical data, are essential to identify similar weaknesses. The vulnerability also highlights the importance of maintaining up-to-date security patches in enterprise applications, as unpatched systems remain prime targets for exploitation. Organizations should also consider implementing data loss prevention measures and conducting regular penetration testing to identify potential attack vectors within their Siebel CRM implementations.